BGM0504 clinical trials
Also written BGM0504.
How each study uses BGM0504 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the BGM0504 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2025 (7)
| Year | Studies |
|---|---|
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 7 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 14 · Other 1
BrightGene Bio-Medical Technology Co., Ltd. (13) · BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd. (1) · Second Affiliated Hospital of Soochow University (1)
Related medicines
As reviewed, each with the page that says it.
- One of GLP-1 receptor agonists source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test BGM0504, phase 3 first.
- Apr 2027A Study of BGM0504 in Participants With Type 2 Diabetes in IndonesiaPhase 3 · BrightGene Bio-Medical Technology Co., Ltd.
- Feb 2027A Study to Evaluate Efficacy and Safety of BGM0504 Tablets in Overweight or Obese Participants Without DiabetesPhase 2 · BrightGene Bio-Medical Technology Co., Ltd.
Studies
Open first, then newest update. How each study uses BGM0504 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 15
- A Study to Evaluate Efficacy and Safety of BGM0504 Tablets in Overweight or Obese Participants Without DiabetesRecruitingPhase 2BrightGene Bio-Medical Technology Co., Ltd.NCT07658560Written as BGM0504 tablets
- A Study of BGM0504 in Early T2DM With ObesityRecruitingPhase 3BrightGene Bio-Medical Technology Co., Ltd.NCT07743983Written as BGM0504
- Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult SubjectsCompletedPhase 1BrightGene Bio-Medical Technology Co., Ltd.NCT07166081Written as BGM0504
- Bioequivalence Study of BGM0504 InjectionCompletedPhase 1BrightGene Bio-Medical Technology Co., Ltd.NCT07382908Written as BGM0504 Injection multi-dose pen
- A Study of BGM0504 Injection in Participants With Obesity or OverweightCompletedPhase 3BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.NCT06704581Written as 5 mg BGM0504 injection
- A Study of BGM0504 in Participants With Type 2 Diabetes in IndonesiaActive, not recruitingPhase 3BrightGene Bio-Medical Technology Co., Ltd.NCT07064486Written as BGM0504
- A Study of BGM0504 in Participants With ObesityCompletedPhase 2BrightGene Bio-Medical Technology Co., Ltd.NCT06911203Written as BGM0504
- A Study of BGM0504 in Overweight or Obese ParticipantsCompletedPhase 1BrightGene Bio-Medical Technology Co., Ltd.NCT06920056Written as BGM0504
- A Study of BGM0504 in Healthy Participants and Participants With Impaired Renal FunctionCompletedPhase 1BrightGene Bio-Medical Technology Co., Ltd.NCT06929156Written as BGM0504
- A Study of BGM0504 Evaluating Weight Loss in Overweight or Obese Chinese SubjectsCompletedPhase 2BrightGene Bio-Medical Technology Co., Ltd.NCT06973681Written as BGM0504
- A Study of BGM0504 Tablets in Healthy and Non-diabetic Overweight or Obese Chinese SubjectsCompletedPhase 1BrightGene Bio-Medical Technology Co., Ltd.NCT07239973Written as BGM0504 tablets
- A Study of BGM0504 Tablets in Healthy Chinese SubjectsCompletedPhase 1BrightGene Bio-Medical Technology Co., Ltd.NCT07566572Written as BGM0504 tablets
- A Study Comparing the Effects of BGM0504 Injection and Semaglutide Injection on Obese Subjects.CompletedPhase 2Second Affiliated Hospital of Soochow UniversityNCT07836140Written as BGM0504 Administered SC
- Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection in Non-diabetic Overweight or Obese Adult SubjectsCompletedPhase 1BrightGene Bio-Medical Technology Co., Ltd.NCT06714955Written as Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week.
- A Study of BGM0504 in Chinese Patients With Type 2 DiabetesCompletedPhase 2BrightGene Bio-Medical Technology Co., Ltd.NCT06974825Written as BGM0504 Administered SC